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Abstract: Prostate cancer is a major threat to men's health around the world. Bone is the most common metastasis site in
patients with prostate cancer, which may lead to bone pain, pathological fracture and spinal cord compression, and it is
related to various physiological or pathological factors such as age, physical condition, and previous treatment. The
occurrence of bone-related events will seriously affect the quality of life of patients. In recent years, more and more
people are concerned about bone metastasis of prostate cancer. Some important international cancer organizations have
issued guidelines for the diagnosis and treatment of prostate cancer with bone metastasis. However, Clinicians still have
some misunderstandings about bone metastasis of prostate cancer, especially selection of therapeutic strategies and the
screening of appropriate drugs. Nowadays, the therapeutic strategies of prostate cancer with bone metastases mainly
include primary lesions and bone metastases lesions. The former include surgery, radiotherapy, endocrine therapy,
chemotherapy, immunotherapy, radiofrequency ablation and so on. And the later is made up of bone modification drug,
radiopharmaceutical, lifestyle adjustment, and symptomatic analgesic treatment. The purpose of this review is to
summarize the status and progression of bone metastasis in prostate cancer and to explore the best diagnosis and
therapeutic strategies.
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Introduction
Prostate cancer (PCa) is one of the most common genitourinary tumors in Caucasian and African Americans. In
particular, the morbidity and mortality of the elderly were at the forefront of malignant tumors. China is a country with
low incidence of prostate cancer, but recently changes in some factors have led to a significant increase in incidence
such as diet, society, environmental factor and so on[1,2]. According to the latest statistics in 2017 by China National
Cancer Center, studies have shown that the incidence of prostate cancer is significantly different in urban and rural areas.
People in major cities, such as Beijing, Shanghai and Guangzhou, are more likely to develop prostate cancer and the
incidence is 17.26 cases per 100,000. On the contrary, the incidence of prostate cancer in some people living in small
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cities or rural areas is less than 5 per 100,000[3]. Prostate cancer has the characteristics of occult and is apt to metastasis
in clinical. Bone is the most common metastatic site and it has been reported that about 70% of prostate cancer patients
in Europe or United States may have bone metastasis in the course of disease, and bone metastasis will seriously affect
the quality of life of patients[4]. The incidence of prostate cancer with bone metastasis in Japan is approximately 75%,
which is also increasing with the extension of the patient's survival[5]. Bone metastasis may lead to bone pain,
pathological fracture and spinal cord compression, which is related to various factors such as age, physical condition,
and previous treatment. At present, people around the world are more concerned about the bone metastasis of prostate
cancer. Some important international cancer organizations have issued guidelines for the diagnosis and treatment of
prostate cancer related bone metastasis[6-8]. The purpose of this review is to summarize the status and progression
of bone metastasis in prostate cancer and to explore the best diagnosis and treatment strategies.
1. Clinical manifestations of prostate cancer with bone metastases
Axial skeleton is the most common site of bone metastasis, which mainly occurs in the thoracic, lumbar spine, ribs,
pelvis and so on, and it usually manifests multifocal metastasis. Prostate cancer with bone metastasis mainly dominated
osteoblastic changes, but there may be osteoblastic and osteolytic coexisting in metastatic bone lesions[9,10]. Patients
with early stages of bone metastasis in prostate cancer may have no associated clinical symptoms. However, as the
disease progresses, pain is the first symptom in about 90 percent of patients with advanced prostate cancer. In addition,
there may be pathological fractures, dyskinesia, spinal cord compression, hypercalcemia, coma, muscle weakness and
paralysis[11]. The first skeletal related events (SREs) may occur 10 months after the diagnosis of prostate cancer. SREs is
defined as bone complications caused by tumor bone metastasis, mainly including pathological fractures, spinal
compression, hypercalcemia, and bone complications requiring surgical or radiotherapy. Acute SREs can affect the
quality of life and survival of patients[7]. Prostate cancer with bone metastasis is quite complicated and the mechanism
has not yet completely clear. It has been clearly related to the transduction and activation of some signaling pathways
until now, such as MET, VEGF, β2-epinephrine signaling pathway, AR signaling pathway and RANKL signaling
pathway[12].
2. Diagnosis of prostate cancer with bone metastasis
Accurate diagnosis of bone metastasis plays an important role in the clinical staging and programming of prostate
cancer. Prostate cancer is similar to other tumors, mainly based on the clinical stage of AJCC. However, due to the high
heterogeneity of prostate cancer, clinicians found that AJCC staging alone could not develop accurate and effective
treatment methods. Therefore, NCCN found that on the basis of AJCC stage, increasing serum PSA level before
treatment and Gleason score could constitute the prognostic risk assessment model of prostate cancer by summarizing
evidence-based medical data. This model may be important for guiding the diagnosis and treatment of prostate cancer[13].
Current studies have found that novel prostate cancer patients with any of the following indicators can be considered as
a high-risk population for bone metastasis, including: A. Bone pain or pathological fracture; B. PSA≥10 ng/ml; C.
Alkaline phosphatase elevated; D. Hypercalcemia; E. Gleason score≥8 points; F. TNM stage≥T3 period[14]. Appropriate
screening for high-risk groups is the key to accurate diagnosis. Bone metastasis in prostate cancer is mainly caused by
osteogenic changes. Osteoblasts can form bone matrix, which can lead to ray impenetrability. However, histological
studies have confirmed that osteoclast activity and resorption cavities can occur at the site of osteogenic lesions,
indicating that there is also an increase in osteolytic activity in all metastatic bone lesions[6]. The diagnosis of prostate
cancer with bone metastasis needs to be combined with the patient's clinical symptoms and advanced examination
equipments, including X-ray, CT, ECT, MRI and PET-CT[15]. In addition, some biochemical markers can be needed
such as Prostate Specific Antigen (PSA), Alkaline Phosphatase (ALP), Bone Sialoprotein (BSP) and Collagen type I
pyridine crosslinking peptide (ICTP). A clinical control study found that the sensitivity of SP, ALP, ICTP and PSA is
80.95%, 57.14%, 69.05% and 71.43%, and the specificity is 72.80%, 64.80%, 76.80% and 88.80%, respectively.
Sensitivity of the combined detection of the above 4 serological markers can be increased to 97.62%, which may
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effectively increase the positive predictive value of prostate cancer with bone metastasis[16].
3. Therapy for prostate cancer with bone metastasis
The treatment of prostate cancer with bone metastases mainly include primary lesions and bone metastases lesions.
The former include surgery, radiotherapy, endocrine therapy, chemotherapy, immunotherapy, radiofrequency ablation
and so on. And the later is made up of bone modification drug, radiopharmaceutical, lifestyle adjustment, and
symptomatic analgesic treatment. This chapter focuses on systemic treatment of prostate cancer and local treatment
of bone metastases lesions.
4. Systemic treatment of prostate cancer
4.1 Endocrine therapy
Endocrine therapy is one of the most common therapeutic methods of prostate cancer. It is also a first-line
treatment for advanced prostate cancer and significantly prolonged the progression free survival and overall survival of
patients. It includes androgen deprivation therapy , single anti-androgen therapy, complete androgen blockading,
androgen biosynthesis inhibitor , neoadjuvant endocrine therapy before radiothreapy, intermittent endocrine therapy and
adjuvant endocrine therapy after radiotherapy and etc[17,18]. Endocrine therapy can be divided into first-line and
second-line endocrine therapy, and the first-line endocrine therapy mainly includes androgen deprivation therapy,
anti-androgen drug therapy, and complete androgen blocking therapy.
4.1.1 Androgen deprivation therapy (ADT)
ADT can inhibit the productions of androgen, reduce estrogen in the body, and remove the stimulating effect of
androgen on the growth of prostate cancer cells. The methods mainly include surgical emasculation (bilateral
orchiectomy) and drug emasculation (LHRH analogues, estrogen). It apply to the following diseases: ①metastatic
prostate cancer; ② localized early-stage or located progressive prostate cancer, no prostatectomy or radiotherapy; ③
neoadjuvant endocrine therapy before radical prostatectomy or radical radiotherapy; ④ adjuvant endocrine therapy
cooperated with radiotherapy; ⑤ localized recurrence and metastasis after curative treatment;⑥continuous androgen
suppression on the stage of androgen-independent. See table 1 basic characteristics of drug emasculation therapy.
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Table 1. Basic characteristics of drug emasculation therapy
4.1.2 Antiandrogen monotherapy (AAM)
AAM can be competitively combined with endogenous androgen receptors in target organs, and it can inhibit the
entry of dihydrotestosterone into the nucleus by binding to the dihydrotestosterone receptor in the cytoplasm,
thereby blocking the effect of androgens on prostate cancer cells. It is mainly applicable to prostate cancer with local
advanced stage and no distant metastasis (T3-4NxM0 stage). According to different chemical structure, it can be divided
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Table 2. Basic characteristics of Anti-androgen therapy
4.1.3 Androgen biosynthesis inhibitor therapy
Abiraterone acetate (AA) belongs to a kind of androgen biosynthesis inhibitors and can inhibit androgen synthesis
of testicular, adrenal and prostate cancer cells by inhibiting CYP17 which is a key enzyme in the androgen synthesis
pathway. The commonly used dosage of AA is 1000mg, orally, once a day. And it is suitable for first-line treatment of
asymptomatic or mild symptoms of metastatic castration resistant prostate cancer (mCRPC), or is not suitable for
chemotherapy in patients with symptomatic mCRPC, or patients with advanced mCRPC after chemotherapy. In the
COU-AA-301 study, the median survival of abiraterone acetate plus prednisone was 15.8 months in patients with
mCRPC who recieved docetaxel after chemotherapy, which was 4.6 months longer than the control group. The risk of
death was reduced by 26%[19]. In the final analysis of the COU- aa-302 study, for patients with mCRPC without
symptoms or mild symptoms, the median survival of abiraterone acetate combined with prednisone is 34.7 months and
the control group is 30.3 months. The median survival extended by 4.4 months and the risk of death reduced by 19%[20].
4.1.4 Complete androgen blocking therapy (CAB)
CAB is also called maximal androgen blockade (MAB). The combination of castration and anti-androgen may
remove testis-derived and adrenal-derived androgen. A combination of castration and anti-androgen therapy can
simultaneously remove androgens from both the source of testis and the source of adrenal gland. Previous studies have
shown that compared with LHRHa alone, CAB composing of LHRHa and bicalutamide can reduce the risk of death in
patients with advanced prostate cancer and prolong their disease-free survival[21]. In recent years, the NCCN and EAU
guidelines have shown that CAB can improve the overall survival of patients by 5-20%.
4.1.5 Neoadjuvant hormone therapy (NHT)
NHT is suitable for advanced prostate cancer patients with T2 and T3a stages. Recommended options include CAB,
LHRH alone or anti-androgen drugs and treatment duration are 3 to 9 months.
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300mg, po, once
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4.1.6 Intermittent endocrine therapy (IHT)
IHT can delay tumor progression to hormone-independent period. It apply to localized prostate cancer that cannot
undergo radical surgery or radiotherapy, or local advanced prostate cancer (T3-T4 stage), or metastatic prostate cancer
with positive pathological margin and recurrence after radical resection. IHT usually adopts CAB, and can also be used
for drug emasculation. The recommended discontinuation rate is 3 to 6 months after PSA is less than or equal to 2ng/ml.
4.1.7 Adjuvant endocrine therapy after radical treatment
The objective of adjuvant endocrine therapy after radical treatment is to treat the marginal residual lesion, residual
positive lymph nodes, small metastatic lesion, etc. Its indications include positive pathologic margin after radical
surgery, positive lymph nodes of postoperative pathological, T3 or T2 stage with high risk factors (Gleason > 7, PSA >
20ng/ml), and local advanced prostate cancer after radical radiotherapy. The main treatment methods include CAB,
drugs or surgical excision, and anti-androgen therapy. It is recommended to start immediately after surgery or
radiotherapy, with a minimum time of 18 months.
4.1.8 Anti-androgen withdrawal therapy
Patients with androgen deprivation therapy, androgen receptor gene mutation may occur and results in the decrease
of the receptor specificity, antiandrogen medicines instead as agonist activation of downstream, eventually lead to
treatment failure. At this point, if the anti-hormone drugs are discontinued, approximately 1/4 of the patients may have a
3-5 month PSA decline and local symptom improvement[22].
4.2 Chemotherapy
Chemotherapy is an important treatment for metastatic castration-resistant prostate cancer (CRPC). Common drugs
include Taxanes, Mitoxantrone, Adriamycin, Epirubicin, Estramustine, Cyclophosphamide, Orally administered
vinorelbine, cisplatin, and fluorouracil. Taxus drugs has become the standard first-line chemotherapy for endocrine
failure in metastatic prostate cancer. However, single drug chemotherapy for advanced prostate cancer has a poor effect.
Currently, the combined drug regimen is recommended, and specific chemotherapy drugs and regimens are shown in
table 3.
Regimens Drugs and Dosage Notes
DP Docetaxel 60-75mg/m2, intravenous
injection, d1;
Prednisone 5mg, po, bid, day 1-21;
Every 21 days.
TAX327 study demonstrated that compared with mitoxantrone,
the median survival was significantly delayed in patients who
received docetaxel 3-week regimen (18.9 vs. 16.5 months,
P=0.009), and PSA response rates (45% vs. 32%, P<0.001), and




Prednisone 5mg, po, bid, day 1-21;
Every 21 days.
For symptomatic hormone-resistant prostate cancer, compared
with monotherapy prednisone, mitoxantrone combined with
prednisone significantly relieved bone pain (29% vs. 12%,
P=0.01), but the overall survival did not extend significantly[24].
EMP Estramustine 600mg/(m2·d), po, bid;
A total of 3-4 months.
With the dual role of alkylating agent and estrogen.
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EEM VP-16 50mg/(m2·d), po, d1-14;
EM 15mg/(kg·d), po, d 1-21;
Every 4 weeks, continuously to disease
progression.
NE Norvinvinine 25mg/m2, intravenous
injection, d1 and d8;
Estramustine 280mg, tid, d1-14;
Every 21 days.







CP Cabaztaxe l25mg/m2, intravenous
injection, d1;
Prednisone 5mg, po, bid, d1-21;
Every 21 days.
TROPIC study showed that compared to mitoxantrone,
cabazitaxel is more effective in failed CRPC patients with PSA
response rate of 39.2%, median PFS of 2.8 months, and 15.1
months of OS[25].
FIRSTANA study showed that cabazitaxel was not superior to
docetaxel in both OS and PFS in patients with metastatic CRPC
who are not received chemotherapy[26].
Table 3. Chemotherapy for advanced prostate cancer
4.3 Immunotherapy
At present, Sipuleucel-T (Provenge) is the only self-tumor vaccine used for the clinical treatment of prostate cancer.
It is mainly adapted to CRPC patients with no symptoms or mild symptoms, no liver metastasis, > life expectancy for 6
months, and generally in good condition. Preparation process was first isolated from patient's body antigen presented
cells, in vitro amplification and incubation activation in the prostatic acid phosphatase (PAP), and then back to the
patient's body, induction of the innate immune response to prostate cancer and achieve the goal of treatment of tumor[27].
In Phase III studies, Sipuleucel-T prolonged the survival of CRPC patients by approximately 4 months compared with
placebo and the survival rate of three-year is 31.7%. However, it is not recommended for patients with rapid disease
progression, liver metastases or patients who are expected to survive for less than 6 months.
5. Treatment of bone metastases in prostate cancer
Currently, the drugs targeted at bone metastases of prostate cancer in clinical practice are mainly bone-modifying
agents (BMAs) and radioactive drugs, among which BMAs include bisphosphate drugs and dino-resistant drugs and
radioactive drugs include Strontium-89 (89Sr), Samarium-153 (153Sm) and Radium-223.
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5.1 Bone-modifying agents
5.1.1 Bisphosphate drugs
Bisphosphate drugs are one of the most commonly used drugs to prevent and treatment for bone metastases related
complications. It can obviously reduce or delay the incidence of bone metastases and some experts recommend starting
treatment as soon as possible when bone metastasis is diagnosed, even in asymptomatic patients. The specific
classification and usage amount are shown in table 4.
Classification
Names Usage and Dosage Indications
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4mg, iv drip, infusion time
should not be less than 15
minutes.
Every 3-4 weeks
Pain caused by osteolytic bone
metastasis in malignant tumors. The
first and only bisphosphonates
approved for use in CRPC patients can
reduce the incidence of SREs.
Table 4. Classification and features of Bisphosphate drugs
5.1.2 Denozomab (D-mab)
Denozomab is a fully human monoclonal antibody of aspecific receptor activator of NF-κB ligand (RANKL)
which may inhibit osteoclast activation to reduce bone resorption and tumor-associated bone destruction. It may have
the effect of breaking the vicious circle caused by bone metastasis and activation of osteoclasts, and is suitable for
treating solid tumors with bone metastasis in adult patients, but not for blood tumors. Fizazi et al. demonstrated that
Denozomab prevents SREs better than zolledronic acid in CRPC patients with bone metastasis, and they found that
compared with zolledronic acid, Denozomab delayed the first SREs onset by 17.1 months and 20.7 months respectively
(P=0.008)[28]. Another Ⅲ period studies have shown that Denozomab can by changing the bone microenvironment and
delay the onset of prostate cancer bone metastasis, the results showed that compared with placebo, bone metastases free
survival time (BMFS) is 4.3 months by Denozomab extending (25.2 months to 29.5 months, p = 0.028), but the two
groups of patients' overall survival are similar (43.9 to 44.8 months, p = 0.91). However, the risk of mandibular
osteonecrosis and hypocalcemia in Denozomab group was higher than that in the placebo group[29]. In addition, Smith
MR et al. found non-metastatic CRPC patients with PSA doubling in a short period of time are at high risk for bone
metastasis. Denozomab can improve the BMFS of PSA doubling patients, especially for high-risk patients with
suspected disease progression[30].
5.2 Radioactive drugs
5.2.1 89Sr and 153Sm
Radionuclide therapy is an effective treatment for bone metastasis of prostate cancer. 89Sr and 153Sm are mainly
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used in the treatment of osteogenic bone metastasis. Both of them have similar effects, which are about 60-80%, but
they are slightly different in terms of pain relief time and toxicity. 89Sr can accumulate in bone metastases with active
osteoblasts, and is an effective internal radiation therapy agent for bone tumors. Its therapeutic effect is mainly to kill
the cancer cells by means of β rays, so as to achieve the analgesic effect. The energy of β rays emitted by 89Sr is
1.46MeV with a half-life of 50.5 days, and it can be rapidly absorbed by bone after injection, with a half-life of 14 days
in normal bone and a half-life of more than 50 days in bone metastases. 153Sm is a radionuclide, produced by
neutron bombardment of concentrated samarium 152 oxides, which is used to develop osteogenic bone metastases.
153Sm can simultaneously emit γ and β rays, which have a very low osteotactic character, while 153Sm-EDTMP, a new
compound formed after the chelation of 153Sm and EDTMP, has a high osteotactic character. The concentration of
153Sm- EDTMP in bone metastases was 5 times that of normal bone tissue, and tumor cells can be continuously
exposed to higher dose of β rays to achieve the purpose of local treatment.
5.2.2 Radium-223
Radium-223 is a α-particle radiation therapy agent, whose activity is partially simulated by calcium ions, and it can
form complex with hydroxyapatite (HAP) in bone and selectively target bone, especially in the area of bone metastasis.
The results on ALSYMPCA study showed that compared with placebo, the median OS of patients in the Radium-223
group was 3.6 months longer (14.9 months vs. 11.3 months, P=0.00007) and reduced the risk of death by 30.5%. The
time to the first SREs was delayed to 5.8 months (15.6 months vs. 9.8 months, P < 0.0001). Subgroup stratification
suggested that patients could benefit from Radium-223 regardless of whether they received paclitaxel chemotherapy
or bisphosphonate[31].
5.3 Other approaches
At present, the treatment of prostate cancer with bone metastases is recommended to carry on the diagnosis and
treatment of multidisciplinary collaboration (MDT). Specialists in oncology, radiotherapy, bone surgery, pathology,
radiography and palliative care are required to participate in the MDT. The ultimate goal is to provide accurate guidance
for the clinical diagnosis and treatment of prostate cancer patients with bone metastasis.
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